Single-Agent Trabectedin vs Physician's Choice Chemotherapy for Recurrent Ovarian Cancer With BRCA Mutation and/or BRCAness Phenotype
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
J. Clin. Oncol 2024 Feb 05;[EPub Ahead of Print], D Lorusso, F Raspagliesi, D Ronzulli, G Valabrega, N Colombo, C Pisano, C Cassani, G Tognon, S Tamberi, G Mangili, S Mammoliti, U De Giorgi, F Greco, AM Mosconi, E Breda, G Artioli, C Andreetta, C Casanova, R Ceccherini, A Frassoldati, V Salutari, S Giolitto, G ScambiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.